资讯

Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit ...
Abstract: A novel amplitude-sampled long-period fiber grating with deep tapering (AS-LPFG-DT) is proposed and experimentally demonstrated, functioning as a multichannel LPFG that efficiently generates ...
AI-leveraged drug development has become an $18 billion industry, but companies in the sector are experiencing some hardships ...
Some wrestling royalty will be part of the next group of potential WWE stars. WWE has revealed the fifth class of its Next In Line (NIL) program, USA TODAY Sports confirmed, with 12 former college ...
Series D extends runway into 2027, advancing first-in-class c-mod DPTX3186 toward proof-of-concept in gastric cancer.Strong ...
Regenxbio's RGX-121 gene therapy for Hunter syndrome is the main catalyst, with FDA approval targeted for February 2026.
Hong Kong, November 9, 2020] Deqi Pharmaceutical Co., Ltd. (" Deqi Pharmaceutical " or " the Company ", together with its subsidiaries, collectively referred to as " the Group "; Stock Code: 6996.HK ) ...
Novonesis and Novo Nordisk have formed a research partnership to study how the gut microbiome can support metabolic health and help prevent obesi ...
EngagesFormerFDADirectorof DivisionofCardiologyandNephrology,Norman Stockbridge, M.D., Ph.D., to Advise on Walden’s Clinical Pipeline in Rare Kidney Diseases ...
INDICATION LEQEMBI ® is indicated for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of ...
WAUKESHA, Wis. (CBS 58) -- As the summer draws to a close, parents and kids alike know school is right around the corner. Before the start of the official school year, Carroll University's first-year ...
Prior to installation, please see the AST Docsite for detailed configuration, troubleshooting (REST changes, HIGH CPU on control plane) info, etc. See the F5 Application Study Tool Labs for an ...